Skip to main content

Treatment Clinical Trials for Gastric (Stomach) Cancer

Review the gastric (stomach) cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 139

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Stomach Cancer with Peritoneal Metastases
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tadalafil in Combination with FLOT Chemotherapy prior to Surgery for the Treatment of Stage I-III Resectable Gastric/Gastroesophageal Junction Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Perioperative Intraperitoneal Paclitaxel for the Treatment of Stage IV Gastric or Gastroesophageal Adenocarcinoma with Carcinomatosis or Positive Cytology
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Ivonescimab in Combination with a Standard Chemotherapy Regimen (FOLFOX) for Controlling Disease Progression in Patients with HER2 Negative Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Tucatinib Given Before Surgery to Patients with HER2 positive Cancers that have Spread to the Brain
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Status: Active
Location: University of California San Francisco, San Francisco, California
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Aldesleukin in Combination with Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer with Peritoneal Metastasis, CONTROL Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Nab-Paclitaxel PIPAC in Combination with Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer and Gastroesophageal Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
KK-LC-1 TCR T Cells for the Treatment of Metastatic Gastric, Lung, Breast, and Cervical Cancers
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
A Study of DM001 in Patients With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas